At the news
? BULLISHIMPACT 7/10 8-K filed Aug 6, 2026 at 07:10 ET
REGENXBIO reported Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus of -$0.11, driven by a $100M AbbVie milestone payment. Revenue surged to $108.0M from $21.4M YoY, but this was entirely milestone-driven; core operations remain loss-making. The company raised $108M in a July offering and ended Q2 with pro-forma cash of ~$313M, extending runway into Q4 2027. Key catalysts include RGX-202 BLA submission in Q3 2026 and pivotal wet AMD data in Q4 2026.
- Q2 2026 GAAP net income of $22.7M ($0.43 EPS) vs consensus -$0.11, a 499% beat.
- Revenue of $108.0M was driven by a $100M AbbVie milestone payment for dosing first patient in NAAVIGATE study.
- Pro-forma cash, cash equivalents and marketable securities of ~$313M as of June 30, 2026, extending runway into Q4 2027.
- Phase III AFFINITY DUCHENNE trial of RGX-202 met primary endpoint with high statistical significance (p<0.0001).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access